ReviewJournal of experimental & clinical cancer research : CR2026
Extrachromosomal DNA and cancer: function, formation, and clinical implications.
Review in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extrachromosomal DNA Amplification as a Prognostic Factor for Cancer.Journal of personalized medicine · 2026Review
- Challenges in the detection and assembly of virus integration structures in human genomes.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Extrachromosomal DNA (ecDNA) is a circular, double-stranded DNA molecule distinct from chromosomal DNA, primarily found in cancer cells as a subtype of extrachromosomal circular DNA (eccDNA). Unlike eccDNAs found in normal cells, cancer-associated ecDNAs are large, clonal, and carry complete oncogenes. These ecDNAs are increasingly recognized as crucial drivers of cancer pathogenesis, contributing significantly to the evolution of tumor heterogeneity and the acquisition of therapeutic resistance through mechanisms such as high-level gene amplification and altered gene regulation. Historically, the understanding of these mobile genetic elements in cancer has been limited. This review synthesizes current knowledge on ecDNA’s structural and functional features, formation mechanisms and roles in cancer initiation, progression and therapeutic resistance. Moreover, we summarize five emerging therapeutic approaches that target ecDNA to inform future cancer research and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.